Statin adherence in patients with high cardiovascular risk: a cross-sectional study

References

• Global health estimates: life expectancy and leading causes of death and disability (2019) [ online].Website https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates. [2021 Aug 23].
   Google Scholar
• Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987;257(16):2176–2180.
   PubMed Web of Science ®Google Scholar
• Mahley RW, Palaoglu KE, Atak Z, et al. Turkish heart study: lipids, lipoproteins, and apolipoproteins. J Lipid Res. 1995;36(4):839–859.
   PubMed Web of Science ®Google Scholar
• Bayram F, Kocer D, Gundogan K, et al. Prevalence of dyslipidemia and associated risk factors in Turkish adults. J Clin Lipidol. 2014;8(2):206–216.
   PubMed Web of Science ®Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–2561.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
   PubMed Web of Science ®Google Scholar
• Treatment Trialists C C, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–590.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058.
   PubMed Web of Science ®Google Scholar
• McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. Arch Internal Med. 1997;157(17):1921–1929.
   PubMedGoogle Scholar
• Chiang CE, Ferrieres J, Gotcheva NN, et al. Suboptimal control of lipid levels: results from 29 countries participating in the centralized pan-regional surveys on the undertreatment of hypercholesterolaemia (CEPHEUS). J Atheroscler Thromb. 2016;23(5):567–587.
   PubMed Web of Science ®Google Scholar
• Gitt AK, Lautsch D, Ferrieres J, et al. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. Atherosclerosis. 2016;255:200–209.
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23(6):636–648.
   PubMed Web of Science ®Google Scholar
• Managing elevated lipids in primary care [cited 2022 July 27] https://ipccs.org/2018/08/22/managing-elevated-lipids-in-primary-care//download-managing-elevated-lipids-in-primary-care.pdf
   Google Scholar
• Al-Foraih M, Somerset S. Factors affecting adherence to statins in hypercholesterolemic Kuwaiti patients: a cross-sectional study. Med Princ Pract. 2017;26(1):35–40.
   PubMed Web of Science ®Google Scholar
• Brown MT, Bussell JK Medication adherence: WHO cares? Mayo Clinic Proceedings 2011; 86:304–314.
   Google Scholar
• Liberopoulos EN, Florentin M, Mikhailidis DP, et al. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf. 2008;7(6):717–725.
   PubMed Web of Science ®Google Scholar
• Ozdemir T, Sahin I, Avci II, et al. Assessment of factors related to statin non-adherence in patients with established coronary artery disease: a single-center observational study. Arch of the Turk Soc of Cardiol. 2017;45(8):723–730.
   PubMed Web of Science ®Google Scholar
• Mann DM, Allegrante JP, Natarajan S, et al. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther. 2007;21(4):311–316.
   PubMed Web of Science ®Google Scholar
• Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the health belief model. Health Educ Q. 1988;15(2):175–183.
   PubMedGoogle Scholar
• Chee YJ, Chan HH, Tan NC. Understanding patients’ perspective of statin therapy: can we design a better approach to the management of dyslipidaemia? A literature review. Singapore Med J. 2014;55(8):416–421.
   PubMed Web of Science ®Google Scholar
• Visseren FLJ, Mach F, Smulders YM. ESC guidelines on cardiovascular disease prevention in clinical practice.Eur Heart J. 2021 [2021 Sep 7];42(34):3227–3337.
   PubMed Web of Science ®Google Scholar
• Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.
   PubMed Web of Science ®Google Scholar
• BS YS. Side effects of medications and adherence to medication in patients using antipsychotics. Florence Nightingale Hemşirelik Dergisi. 2012;20(2):93–103.
   Google Scholar
• Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Eval of Mental Disord. Patient Health Questionnaire. JAMA. 1999;282(18):1737–1744.
   Google Scholar
• Sar YE, Kokoglu B, Balcıoğlu H, et al. Turkish reliability of the patient health questionnaire-9. Biomed Res. 2016;27( Special Issue):460–462.
   Google Scholar
• Bouchard MH, Dragomir A, Blais L, et al. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol. 2007;63(6):698–708.
   PubMed Web of Science ®Google Scholar
• Natarajan N, Putnam RW, Yip AM, et al. Family practice patients’ adherence to statin medications. Can Family Physician. 2007;53(12):2144–2145.
   PubMedGoogle Scholar
• Katzmann JL, Mahfoud F, Bohm M, et al. Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk. Patient Prefer Adherence. 2019;13:9–19.
   PubMed Web of Science ®Google Scholar
• Bermingham M, Hayden J, Dawkins I, et al. Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care. Clin Ther. 2011;33(9):1180–1189.
   PubMed Web of Science ®Google Scholar
• Wouters H, Van Dijk L, Geers HC, et al. Understanding statin non-adherence: knowing which perceptions and experiences matter to different patients. PLoS One. 2016;11(1):e0146272.
   PubMed Web of Science ®Google Scholar
• Warren JR, Falster MO, Fox D, et al. Factors influencing adherence in long-term use of statins. Pharmacoepidemiol Drug Saf. 2013;22(12):1298–1307.
   PubMed Web of Science ®Google Scholar
• Grant RW, O’Leary KM, Weilburg JB, et al. Impact of concurrent medication use on statin adherence and refill persistence. Arch Internal Med. 2004;164(21):2343–2348.
   PubMedGoogle Scholar
• Sulaiman N, Hamdan A, Tamim H, et al. The prevalence and correlates of depression and anxiety in a sample of diabetic patients in Sharjah, United Arab Emirates. BMC Fam Pract. 2010;11(1):80.
   PubMed Web of Science ®Google Scholar
• Rezende Macedo Do Nascimento RC, Mueller T, Godman B, et al. Real-world evaluation of the impact of statin intensity on adherence and persistence to therapy: a Scottish population-based study. Br J Clin Pharmacol. 2020;86(12):2349–2361.
   PubMed Web of Science ®Google Scholar
• Woerkom M, Piepenbrink H, Godman B, et al. J Comp Eff Res. Journal of Comparative Effectiveness Research. 2012;1(6):527–538.
   PubMed Web of Science ®Google Scholar